BRIUMVI
ublituximab
Listed by TG Therapeutics, Inc.
- Strength
- 150 mg/6mL
- Form
- Injection, Solution, Concentrate
- Route
- Intravenous
- Class
- CD20-directed Cytolytic Antibody
What it contains
- Ublituximab 150 mg/6mL
FDA record
| Dosage form | Injection, Solution, Concentrate |
|---|---|
| Route | Intravenous |
| Drug class | CD20-directed Cytolytic Antibody |
| Approval route | BLA — biologic licence |
| NDC code | 73150-150 |
| FDA application | BLA761238 |
| RxNorm concept | 2626353 |
| Package sizes listed | 1 |
| Marketed since | December 2022 |
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.